
The study aimed to prospectively determine protein biomarkers that predict MACE in hypertrophic cardiomyopathy and to identify signalling pathways differentially regulated in patients who subsequently develop MACE. The study included 245 patients. This study is the first to demonstrate the ability of proteomics profiling to predict MACE in hypertrophic cardiomyopathy, exhibiting both novels (eg, Ras-MAPK) and known (eg, TGF-β) pathways differentially regulated in patients who subsequently experience MACE.
Like
Save
Share